|
1）Takahashi T, Takahashi K, Gerety S, et al. Temporally compartmentalized expression of ephrin-B2 during renal glomerular development. J Am Soc Nephrol. 2001; 12(12): 2673-82
|
|
|
|
2）Usui J, Yamada R, Kanemoto K, et al. Murine metanephric mesenchyme possesses characteristics of vascular endothelial cells in vitro. Nephron Exp Nephrol. 2006; 102(3-4): e93-8
|
|
|
|
|
|
3）Moeller MJ, Kovari IA, Holzman LB, et al. Evaluation of a new tool for exploring podocyte biology: mouse Nphs1 5’ flanking region drives LacZ expression in podocytes. J Am Soc Nephrol. 2000; 11(12): 2306-14
|
|
|
|
|
|
4）Wong MA, Cui S, Quaggin SE, et al. Identification and characterization of a glomerular-specific promoter from the human nephrin gene. Am J Physiol Renal Physiol. 2000; 279(6): F1027-32
|
|
|
|
|
|
5）Moeller MJ, Sanden SK, Soofi A, et al. Two gene fragments that direct podocyte-specific expression in transgenic mice. J Am Soc Nephrol. 2002; 13(6): 1561-7
|
|
|
|
|
6）Matsusaka T, Xin J, Niwa S, et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol. 2005; 16(4): 1013-23
|
|
|
|
|
|
7）Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010; 21(11): 1835-41
|
|
|
|
|
|
8）George M, Rainey MA, Naramura M, et al. Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4. PLoS One. 2011; 6(3): e17838
|
|
|
|
|
|
9）Slater SC, Ramnath RD, Uttridge K, et al. Chronic exposure to laminar shear stress induces Kruppel-like factor 2 in glomerular endothelial cells and modulates interactions with co-cultured podocytes. Int J Biochem Cell Biol. 2012; 44(9): 1482-90
|
|
|
|
|
|
10）Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol. 2011; 26(4): 523-33
|
|
|
|
|
|
11）竹内 啓. 血管新生阻害薬の作用機序と臨床開発-抗 VEGF 抗体・VEGF trap・VEGF-TKI など-. 最新医学. 2008; 63(1): 45-50
|
|
|
|
|
12）Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49: 186-93
|
|
|
|
|
|
13）Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11): 1129-36
|
|
|
|
|
|
14）Takahashi D, Nagahama K, Tsuura Y, et al. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol. 2012; 16(2): 310-5
|
|
|
|
|
|
15）Muller-Deile J, Schiffer M. Renal Involvement in preeclampsia: Similarities to VEGF ablation therapy. J Pregnancy. volume 2011, Article ID 17693
|
|
|
|
|
|
16）Li F, Hagaman JR, Takanashi N, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol. 2012; 23(4): 652-60
|
|
|
|
|
|
17）Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia, Am J Obstet Gynecol. 2007; 196(4): 320. e1-7
|
|
|
|
|
|
18）Eremina V, Jefferson JA, Kowalewska J. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11): 1129-36
|
|
|
|
|
|
19）Nochy D, Lefaucheur C, Hill G. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 359(2): 206
|
|
|
|
|
|
20）Schumacher VA, Schlotzer-Schrehardt U, Karumanchi SA. WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier. J Am Soc Nephrol. 2011; 22(7): 1286-96
|
|
|
|
|